



A bronchoscopic lung volume technique designed to treat late stage emphysema segmentally for patients who are non-surgical candidates


Uptake Medical®

A Broncus Company

PATIENT SELECTION

BTVA is the first personalized treatment for late stage emphysema patients that allows targeted treatment of the most diseased segments of the lung while preserving the healthier segments. It is currently indicated for patients with upper lobe-predominant emphysema.

BTVA can be considered for patients for whom treating of a whole lobe of the lung is not appropriate based on the presence of more healthy lung segments located in the target lobe(s). The advantage of BTVA is the ability to personalize the treatment plan to the actual distribution of disease for the individual patient. The therapy has been proven effective independent of Collateral Ventilation (CV) status and therefore may be suitable for a larger percent of the late stage emphysema population. 1, 2



BLVR: Bronchoscopic Lung Volume Reduction BTVA: Bronchoscopic Thermal Vapor Ablation EBV: Endobronchial Valve

1/ GOLD Guidelines 2020. p 109/110

LVRS: Lung Volume Reduction Surgery

Non-Surgical Treatment Options: BTVA and EBV 1



Complete fissures, CV-

Non-Surgical Treatment Options: Only BTVA 1, 2



Incomplete fissures, CV+

2/ Gompelmann et al. - Respiration 2016;92:397-403 - Lung Volume Reduction with Vapor Ablation in Presence of Incomplete Fissures: 12-Month Results from the STEP-UP Randomized Controlled Study

Bronchoscopic Thermal Vapor Ablation (BTVA®) treatment included in the

2020 GOLD Guidelines

Uptake Medical® A Broncus Company

CONTACT

Uptake Medical®, a Broncus Company Email: info@uptakemedical.com or contact your local representative